ABSTRACT
P300 and cerebrospinal fluid neurotransmitter metabolites and amino acids were examined in 10 patients with Alzheimer's disease, 9 patients with vascular dementia and 10 healthy controls. A negative correlation between P300 amplitude and MHPG concentration, negative correlation between P200 and N200 latencies and norepinephrine concentration, positive correlation between N200 latency and lysine concentration and positive correlation between N100 amplitude and tyrosine concentration were statistically significant. These findings suggest that the noradrenergic system influences P300 amplitude, and that multiple systems may influence P300 components.
Subject(s)
Event-Related Potentials, P300 , Neurotransmitter Agents/cerebrospinal fluid , 3-Methoxy-4-hydroxyphenylethanol/cerebrospinal fluid , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/physiopathology , Dementia, Vascular/cerebrospinal fluid , Dementia, Vascular/physiopathology , Humans , Lysine/cerebrospinal fluid , Middle Aged , Norepinephrine/cerebrospinal fluid , Tyrosine/cerebrospinal fluidABSTRACT
Free and conjugated lumbar cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol (MHPG) was measured before and after probenecid treatment in 12 schizophrenic patients by a gas liquid chromatography-mass fragmentographic procedure. Neither the free nor conjugated MHPG was appreciably altered by probenecid. Total MHPG was statistically increased by probenecid but not to the point that the probenecid test would be clinically useful for estimating norepinephrine turnover from probenecid-induced changes in MHPG concentrations.
Subject(s)
3-Methoxy-4-hydroxyphenylethanol/cerebrospinal fluid , Catechols/cerebrospinal fluid , Probenecid/pharmacology , Adult , Female , Humans , Male , Stimulation, ChemicalABSTRACT
The pharmacological effects of the thyrotropin-releasing hormone (TRH) in relation to biogenic amine metabolism in cerebrospinal fluid were examined in 35 patients with various spinal disorders. Neurologic conditions before and after TRH treatment were evaluated using subjective symptoms and Frankel's classification. Biogenic amine metabolism in cerebrospinal fluid was examined before and after TRH treatment measuring the metabolites by high performance liquid chromatography with electrochemical detection. Significant decreases in metabolites of norepinephrine and dopamine were seen in most cases of spinal disorders. The amount of serotonin metabolite, however, was not changed. In many acute cases, the neurologic condition was improved, and a significant increase in the dopamine metabolite was seen in the improved cases after TRH treatment. In chronic cases, TRH treatment was not as effective as in acute cases. TRH was therefore thought to be an effective agent in the treatment of acute spinal disorders. When an increase in the dopamine metabolite is seen after TRH treatment, neurologic improvement would probably be expected.
Subject(s)
3-Methoxy-4-hydroxyphenylethanol/cerebrospinal fluid , Catechols/cerebrospinal fluid , Dopamine/cerebrospinal fluid , Homovanillic Acid/cerebrospinal fluid , Spinal Diseases/cerebrospinal fluid , Thyrotropin-Releasing Hormone/pharmacology , Adult , Aged , Drug Evaluation , Female , Humans , Male , Middle Aged , Neurologic Examination , Prognosis , Spinal Diseases/drug therapy , Thyrotropin-Releasing Hormone/therapeutic useABSTRACT
A case of Kleine-Levin syndrome with true hypersomnia and a case of sub-wakefulness are described. In both patients lumbar cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylethylene glycol levels have been assayed during episodes of hypersomnia and normal sleep-waking cycles. Besides an increased 5-hydroxytryptamine turnover, mainly an increased dopamine turnover has been detected in both kinds of hypersomnia, and this finding was more remarkable in the case with sub-wakefulness. The probable role of dopamine in abnormalities in the sleep-waking cycle is discussed on the basis of results in experimental animal hypersomnias.